UNSPSC 51413701: Buflomedil

This classification denotes a phosphodiesterase inhibitor with the molecular formula C17H25NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V7I71DQ432, chemically known as 4-(1-pyrrolidinyl)-1-(2,4,6-trimethoxyphenyl)-1-butanone but generally known as buflomedil, which bears US NIH Compound Identifier 2467. Buflomedil most often comes in base and hydrochloride forms. European Medicines Agency schedules Buflomedil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05963MIG.

UNSPSC 51413701 Buflomedil, a Commodity code, nominally identifies a specific vasodilator medication, but recent state and local procurement activity tagged under this code centers on advanced life support medications and pharmaceutical supply agreements spanning multiple drug classes and OTC products. State and local governments procure emergency medications, generic pharmaceuticals, and over-the-counter products through this taxonomy entry, with issuing bodies ranging from municipal fire departments to state health agencies and multi-state cooperative purchasing consortiums. The City of Tampa's Fire Rescue division solicited sealed bids for four specific advanced life support medications (Labetalol, Epinephrine, Adenosine, Diltiazem) in April 2026, while the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by Minnesota's Department of Administration, issued an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products to supply participating state and local facilities across multiple states including Oregon. These procurements require vendors to meet FDA compliance, Good Manufacturing Practices certification, Drug Supply Chain Security Act compliance, and OSHA Hazard Communication Standards for safety documentation.

Recent activity shows concentration in Florida and the Upper Midwest. The City of Tampa's IFB for Advanced Life Support Medications (solicitation 26P00188, due April 8, 2026) carried an estimated contract value of $40,000 with a one-year term and two optional renewals, featuring a 5 percent Small Local Business Enterprise (SLBE) bid discount. MMCAP's RFP (solicitation S1070000015802, due March 26, 2026) established a two-year multi-award framework for generic pharmaceuticals distributed through three authorized wholesalers—AmerisourceBergen, Cardinal Health, and Morris & Dickson—with products effective July 1, 2026; the RFP weighted price competitiveness at 75 percent and required vendors to maintain $5,000,000 commercial general liability insurance. The Texas Health and Human Services Commission issued an RFI (HHS0017013, posted April 3, 2026) to solicit vendor capabilities for direct-to-manufacturer prescription programs serving self-insured health plans and state agencies, reflecting the state's exploratory phase before formal RFP issuance. No incumbent vendor data or specific budget totals are disclosed across these opportunities.